No Data
No Data
Arch Biopartners Receives Approval From Alberta Health Services to Proceed With Phase II Trial
Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
Arch Biopartners Closes Non-Brokered Private Placement
Arch Biopartners Arranges Non-Brokered Private Placement
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed With Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
No Data